- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04914767
Nigella 5 in the Treatment of SARS COV2 (COVID-19) (Nigelle5)
The Effectiveness of Nigella Sativa in the Treatment of SARS COV2 (COVID-19)
The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet.
This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the absence of proven antiviral therapy or specific vaccination against COVID-19, Nigella seed oil is suggested as a potential supplement due to its known immunostimulatory and antiviral activities in previous published studies.
Nigella (known as black seed) in the Latin language or "Habatulbarakah" in the Arabic language, is a food supplement and a medicinal plant well known in Arab and Islamic culture. It is used as a food spice and it has a lot of medical claims that come from different historical backgrounds. Nigella seeds contain several active compounds that have been isolated, identified and reported, the most important being thymoquinone.
In the literature, black seed has shown several pharmacological activities, including anti-inflammatory, antiviral and immunostimulatory activities.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Itinéraire Ceinture Cité Sahloul
-
Sousse, Itinéraire Ceinture Cité Sahloul, Tunisia, 4054
- HU Sahloul, sousse, Tunisia
-
-
Sousse
-
Sahloul, Sousse, Tunisia
- Riadh Boukef
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: patients included in the two studies NIGCOV1 and NIGCOV2 must be:
- Men and women at least 40 years old, able and willing to give informed consent;
- Ambulatory (NIGCOV1) or hospitalized (NIGCOV2) environment;
- Patient with dyspnea or with a positive gait test (NIGCOV2);
- The patient must have at least one of the following high risk criteria: 70 years or older, obesity (BMI ≥ 30 kg / m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥ 150 mm Hg), respiratory disease known (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary artery disease, fever ≥ 38.4 ° C within the last 48 hours, dyspnea at the time of presentation (only patients included on NIGCOV2), bicytopenia, pancytopenia or a combination of a number high neutrophils and low lymphocytes count (only patients included on NIGCOV2);
- The patient is not of childbearing age, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing age and uses at least one method of contraception and preferably two complementary forms of contraception comprising a method of barrier throughout the study and for 30 days after the end of the study;
- The patient must be able and willing to comply with the requirements of this study protocol.
Exclusion Criteria:
- Patient currently in shock or exhibiting hemodynamic instability;
- Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption;
- Pregnant or breastfeeding patient
- Patient with a history of allergic reaction or significant sensitivity to Nigella;
- The patient is considered by the investigator, for whatever reason, to be an unsuitable candidate for the study.
Given the non-homogeneity of the patients, the study population will be divided into two groups:
- group of outpatients: Ambulatory patients = NIGCOV1 study
- and inpatient group: Hospitalised patients = NIGCOV2 study Statistical analysis will be carried out for each group separately
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nigella
The patient will receive a study treatment containing 100 capsules:
|
The patient will receive a study treatment containing 100 capsules:
|
PLACEBO_COMPARATOR: Placebo Group
The patient will also receive a study treatment containing 100 capsules:
|
The patient will receive a study treatment containing 100 capsules:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Death or readmission or requiring oxygen supplementation
Time Frame: one months
|
The composite of death or need for hospitalization or requiring oxygen supplementation due to COVID-19 infection within the first 30 days of randomization
|
one months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death Rate
Time Frame: one month
|
The occurrence of death within 30 days of randomization
|
one month
|
Rate of Requiring oxygen supplementation
Time Frame: one month
|
Number of participants requiring oxygen supplementation
|
one month
|
Rate of Hospiatalization
Time Frame: one month
|
Number of participants requiring hospitalization due to COVID19 infection
|
one month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NigCOV1&2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV2 Infection
-
Centre Hospitalier Universitaire DijonUnknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
University Hospital, LilleFondation Santé RoquetteCompleted
-
University of AarhusCompleted
-
University Hospital, LilleFondation Santé RoquetteUnknown
-
Medical University of ViennaWithdrawnSars-CoV2 | Prophylaxis | Infection Viral | Healthcare Worker
-
Colorado School of Public HealthUniversity of Colorado, Denver; University of Colorado, Boulder; Colorado State... and other collaboratorsRecruitingCOVID-19 | SARS-CoV2 InfectionUnited States
Clinical Trials on Nigella
-
Cairo UniversityCompleted
-
Hôpital Universitaire SahloulCompleted
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, MakkahCompletedCovid19 | ImmunodeficiencySaudi Arabia
-
Tanta UniversityUnknownNigella Sativa With Beta Thalassemia MajorEgypt
-
Indonesia UniversityUnknownHypertensionIndonesia
-
Aga Khan UniversityCompletedHypertension | Diabetes Mellitus | Hypercholesterolemia | Metabolic Syndrome XPakistan
-
Hillel Yaffe Medical CenterUnknownNonalcoholic Steatohepatitis | Liver SteatosisIsrael
-
Sohaib AshrafRecruiting
-
Novatek PharmaceuticalsCompletedCovid19United States